By Angel Blair Time flies. You can say that again, and again, and again. It’s hard to believe that the end of 2025 is upon us and a new year is right around the corner. The year brought many changes, … Continue reading → Source:…
Regular physical activity was independently linked to lower disability, fatigue, and depression over time in people with multiple sclerosis (MS), a new study found. Other lifestyle factors also supported better outcomes. For example, eating a higher-quality diet was independently associated with less disability, while not…
A few months ago in Barcelona, at the annual conference of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), thousands of participants from dozens of countries convened for Patient Community Day 2025 (PCD). This annual event brings together researchers focused on multiple…
Tweet ProfG is on his crusade to target EBV….There are many ways to do this and one route is anti-virals and this is one example….Sounds interesting. Brincidofovir (BCV) is a broad-spectrum anti-viral agent and lipid-conjugate of cidofovir. The intracellular active form of BCV is known…
Tweet This a paper on the methods behind the remyelination trial that has been completed and preliminary results reported….so I am not really sure what the value is….surely one could wait and give the trial design and the results. These types of papers help you…
The U.S. Food and Drug Administration (FDA) has given tentative approval to Lupin’s Siponimod tablets, a bioequivalent version of Mayzent (siponimod), to treat people with relapsing forms of multiple sclerosis (MS). According to a company press release, the therapy is indicated for use in adults with clinically isolated syndrome,…
A Georgia State University researcher won a $1 million U.S. Department of Veterans Affairs (VA) grant to study whether a program combining cognitive training with exercise can help prevent falls in older adults with multiple sclerosis (MS). “Falls are so common — and frightening —…
Tweet The answer to the question above is no, but they all deplete B cells…this study looks at T and B cells after depletion with ublituximab and T cells drop transiently naive B cells show rapid and long term depletion. The depletion reproduced from paper…
Tweet This study examines changes in the gut bacteria after ocrelizumab….it changes and MS is inhibited is it cause or effect..it is hard to prove Ocrelizumab transiently alters microbiota and modulates immune response depending on treatment outcome. Coufal S, Zakostelska ZJ, Thon T, Roubalova R,…
Happy Monday, y’all! I hope you enjoyed your weekend and that you were able to do something that brought you joy. My weekend was spent reading and doing a few things around our house. Considering I have read 20 books so far this year, I…